A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
== Function == PnuC of Salmonella typhimurium and Haemophilus influenzae are believed to function cooperatively with NadR homologues, multifunctional proteins that together with PnuC, participate in NR phosphorylation, transport and transcriptional regulation. NadR, a cytoplasmic protein that is partly membrane associated, contains one well conserved and one poorly conserved mononucleotide-binding consensus sequence (G-X4 GKS). It drives transport and may render transport responsive to internal pyridine nucleotide levels. While its N-terminal half functions as a repressor, its C-terminal half functions as an NR kinase in a putative group translocation process.
==== Alternative medicine ==== Health consumers sometimes confuse the terms "wellness" and "well-being". Wellness is a term more commonly associated with alternative medicine which may or may not coincide with gains in subjective well-being. In 2014, the Australian Government reviewed the effectiveness of numerous complementary therapies: they found low-moderate quality evidence that the Alexander technique, Buteyko, massage therapy (remedial massage), tai chi and yoga are helpful for certain health conditions. On the other hand, the balance of evidence indicates that homeopathy, aromatherapy, bowen therapy, Feldenkrais, herbalism, iridology, kinesiology, pilates, reflexology and rolfing shiatsu were classed as ineffective.
Reptiles interaction also contribute to chemical ecology via bioaccumulation or neutralization of toxic compounds. Diablito poison frog (Oophaga sylvatica) which feeds on leaf litter arthropods sequesters the poison cardenolides with no self harm. Species of dart frogs have evolved in similar fashion to the insects they consume via modification to their Na+/K+-ATPase. Again, similar to the insects they prey upon, the dart frog physiology has changed to allow for secretion of toxic chemicals such as batrachotoxins found on the skin of certain neotropical dendrobatid frogs. Modification to the Na+/K+-ATPase illustrates a co-evolution based on a predator-prey arms race where each must keep evolving to survive. Another example is the interactions between the horned lizards (Phrynosoma spp.) and harvester ants (Pogonomyrmex spp.). Horned lizards evolution has shown the blood contains a factor that metabolizes toxins produced by harvester ants. The metabolized poison is broken down and used in a specialized blood squirting defensive mechanism to defend the horned lizard against predators.
Several efforts to develop standards in the NGS field have been attempted to address these challenges, most of which have been small-scale efforts arising from individual labs. Most recently, a large, organized, FDA-funded effort has culminated in the BioCompute standard. On 26 October 1990, Roger Tsien, Pepi Ross, Margaret Fahnestock and Allan J Johnston filed a patent describing stepwise ("base-by-base") sequencing with removable 3' blockers on DNA arrays (blots and single DNA molecules). In 1996, Pål Nyrén and his student Mostafa Ronaghi at the Royal Institute of Technology in Stockholm published their method of pyrosequencing. On 1 April 1997, Pascal Mayer and Laurent Farinelli submitted patents describing DNA colony sequencing. The DNA sample preparation and random surface-polymerase chain reaction (PCR) arraying methods described in this patent, coupled to Roger Tsien et al.'s "base-by-base" sequencing method, is now implemented in Illumina's Hi-Seq genome sequencers. In 1998, Phil Green and Brent Ewing of the University of Washington described their phred quality score for sequencer data analysis, a landmark analysis technique that gained widespread adoption, and which is still the most common metric for assessing the accuracy of a sequencing platform. Lynx Therapeutics published and marketed massively parallel signature sequencing (MPSS), in 2000.
Sources: en.wikipedia.org
== Role in wound healing == A transepithelial potential (TEP) is created by a difference in ion concentrations across a tissue barrier in the body. In humans, a gradient exists between the outermost and innermost layers of skin across the entire body. This gradient can range from 10mV to 60mV, depending on which part of the body is measured. The potential is created by epithelial cells, which pump Cl− ions out of the skin through the apical membrane and transport Na+ ions to the basal side of the epithelium. This is supported by an experiment in which Na+ and Cl− transport was increased by addition of AgNO3, and a corresponding increase in membrane potential was observed. Furosemide, a Cl− efflux inhibitor, also decreased the strength of the field in corneal cells. These potentials are maintained elsewhere on the body, such as in the GI, urinary, and respiratory ducts, as well as the corneal epithelium. When the epithelium is pierced by some kind of wound, the barrier which establishes the electric potential has been removed, and so the TEP cannot be maintained. This creates a lateral EF, running from intact epithelium toward the edges of the wound. These wound EFs last as long as the wound takes to heal, and are involved in guiding various types of cells toward the injury in order to facilitate recovery These lateral fields arise instantaneously upon disruption of the epithelium and gradually increase to their maximum strength. The current strength then declines but is maintained throughout the healing process.
Dyer and Nicholas Perpick, the Mississauga-based company operates in Canada and the US. Prime Restaurants was acquired by Fairfax Financial, and many of their East Side Mario's locations have either closed or been converted to Prime Pubs. The Pat and Mario's restaurants have been closed.
Belize is on the Caribbean coast of northern Central America. It shares a border on the north with the Mexican state of Quintana Roo, on the west with the Guatemalan department of Petén, and on the south with the Guatemalan department of Izabal. To the east in the Caribbean Sea, the second-longest barrier reef in the world flanks much of the 386 kilometres (240 mi) of predominantly marshy coastline. The area of the country totals 22,960 square kilometres (8,865 sq mi), an area slightly larger than El Salvador, Israel, New Jersey, or Wales. The many lagoons along the coasts and in the northern interior reduces the actual land area to 21,400 square kilometres (8,263 sq mi). It is the only Central American country with no Pacific coastline. Belize is shaped roughly like a rhombus that extends about 280 kilometres (174 mi) north-south and about 100 kilometres (62 mi) east-west, with a total land boundary length of 516 kilometres (321 mi). The undulating courses of two rivers, the Hondo and the Sarstoon River, delineate much of the country's northern and southern boundaries. The western border follows no natural features and runs north–south through lowland forest and highland plateau. The north of Belize consists mostly of flat, swampy coastal plains, in places heavily forested. The flora is highly diverse considering the small geographical area. The south contains the low mountain range of the Maya Mountains. The highest point in Belize is Doyle's Delight at 1,124 m (3,688 ft).
Sources: en.wikipedia.org
The new tools of molecular biology changed the study of bird systematics, which changed from being based on phenotype to the underlying genotype. The use of techniques such as DNA–DNA hybridization to study evolutionary relationships was pioneered by Charles Sibley and Jon Edward Ahlquist, resulting in what is called the Sibley–Ahlquist taxonomy. These early techniques have been replaced by newer ones based on mitochondrial DNA sequences and molecular phylogenetics approaches that make use of computational procedures for sequence alignment, construction of phylogenetic trees, and calibration of molecular clocks to infer evolutionary relationships. Molecular techniques are also widely used in studies of avian population biology and ecology.
FMN + NAD(P)H + H+ The 3 substrates of this enzyme are FMNH2, NAD+, and NADP+, whereas its 4 products are FMN, NADH, NADPH, and H+. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is FMNH2:NAD(P)+ oxidoreductase. Other names in common use include NAD(P)H-FMN reductase, NAD(P)H-dependent FMN reductase, NAD(P)H:FMN oxidoreductase, NAD(P)H:flavin oxidoreductase, NAD(P)H2 dehydrogenase (FMN), NAD(P)H2:FMN oxidoreductase, SsuE, riboflavin mononucleotide reductase, flavine mononucleotide reductase, riboflavin mononucleotide (reduced nicotinamide adenine dinucleotide, (phosphate)) reductase, flavin mononucleotide reductase, and riboflavine mononucleotide reductase.
== History == Since its discovery in 1967, serine protease DPP-4 has been a popular subject of research. Inhibitors of DPP-4 have long been sought as tools to elucidate the functional significance of the enzyme. The first inhibitors were characterized in the late 1980s and 1990s. Each inhibitor was important to establish an early structure activity relationship (SAR) for subsequent investigation. The inhibitors fall into two main classes, those that interact covalently with DPP-4 and those that do not. DPP-4 is a dipeptidase that selectively binds substrates that contain proline at the P1-position, thus many DPP-4 inhibitors have 5-membered heterocyclic rings that mimic proline, e.g. pyrrolidine, cyanopyrrolidine, thiazolidine and cyanothiazolidine. These compounds commonly form covalent bonds to the catalytic residue Ser630. In 1994, researchers from Zeria Pharmaceuticals unveiled cyanopyrrolidines with a nitrile function group that was assumed to form an imidate with the catalytic serine. Concurrently other DPP-4 inhibitors without a nitrile group were published but they contained other serine-interacting motifs, e.g. boronic acids, phosphonates or diacyl hydroxylamines. These compounds were not as potent because of the similarity of DPP-4 and prolyl oligopeptidase (PEP) and also suffered from chemical instability. Ferring Pharmaceuticals filed for patent on two cyanopyrrolidine DPP-4 inhibitors, which they published in 1995. These compounds had excellent potency and improved chemical stability. In 1995, Edwin B.
Meso-zeaxanthin (3R,3′S-zeaxanthin) is a xanthophyll carotenoid, and is one of the three stereoisomers of zeaxanthin. The meso- form is the second most abundant in nature, after 3R,3′R-zeaxanthin, which is produced by plants and algae. Meso-zeaxanthin has been identified in specific tissues of marine organisms and in the macula lutea, also known as the "yellow spot" of the human retina.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.